Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta …
M Yang, Y Li, Y Jiang, S Guo, JQ He… - European Respiratory …, 2023 - Eur Respiratory Soc
… Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among
patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials. Int …
patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials. Int …
Comment on: Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review …
P Almagro, P Martinez-Camblor - European Respiratory …, 2023 - Eur Respiratory Soc
… risk of major adverse cardiovascular events (MACE) in COPD patients with dual bronchodilatation
(long-acting β2 agonist (LABA)/long-acting … (LABA/LAMA/inhaled corticosteroids (ICS)) …
(long-acting β2 agonist (LABA)/long-acting … (LABA/LAMA/inhaled corticosteroids (ICS)) …
Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a …
M Yang, Y Li, Y Jiang, S Guo, JQ He, DD Sin - Eur Respir J, 2022 - Eur Respiratory Soc
… ICS/LABA for MACE according to whether the inhalation device was … cardiovascular disease
Myocardial infarction The presence of acute myocardial injury detected by abnormal cardiac …
Myocardial infarction The presence of acute myocardial injury detected by abnormal cardiac …
Association between Inhaled β2-agonists Initiation and Risk of Major Adverse Cardiovascular Events: A Population-based Nested Case-Control Study
… Citation4 β 2 -adrenoceptors agonists, including long-acting and short-acting β 2 -agonists
(… (PRN) short-acting bronchodilators (ie, SABAs) to be used alongside an ICS or an ICS/LABA …
(… (PRN) short-acting bronchodilators (ie, SABAs) to be used alongside an ICS or an ICS/LABA …
Dual versus single long‐acting bronchodilator use could raise acute coronary syndrome risk by over 50%: A population‐based nested case–control study
L Parkin, S Williams, K Sharples… - Journal of internal …, 2021 - Wiley Online Library
… to history of cardiovascular disease, ethnicity, and concomitant inhaled corticosteroid (ICS) …
risk of adverse cardiovascular events in users of two versus one long-acting bronchodilator – …
risk of adverse cardiovascular events in users of two versus one long-acting bronchodilator – …
Risk assessment of acute myocardial infarction and stroke associated with long-acting muscarinic antagonists, alone or in combination, versus long-acting beta2 …
C Rebordosa, E Plana, A Rubino… - … Pulmonary Disease, 2022 - Taylor & Francis
… of stroke, heart attack, or death associated with tiotropium bromide inhalation powder (… to
compare the risk of acute myocardial infarction (AMI), stroke, or major adverse cardiac events (…
compare the risk of acute myocardial infarction (AMI), stroke, or major adverse cardiac events (…
Is the use of two versus one long-acting bronchodilator by patients with COPD associated with a higher risk of acute coronary syndrome in real-world clinical practice?
L Parkin, S Williams, D Barson… - BMJ open …, 2021 - bmjopenrespres.bmj.com
… of ischaemic cardiovascular disease, ethnicity, and ICS exposure, we … cardiovascular risk
with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease…
with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease…
Long-term inhaled corticosteroid treatment in patients with chronic obstructive pulmonary disease, cardiovascular disease, and a recent hospitalised exacerbation …
A Papi, G Forini, M Maniscalco, E Bargagli… - European Journal of …, 2024 - Elsevier
… comorbidities, increasing the risk of hospitalised COPD exacerbations (H-… an inhaled
corticosteroid (ICS) to long-acting bronchodilator(s) (LABDs) in patients with COPD and cardiac …
corticosteroid (ICS) to long-acting bronchodilator(s) (LABDs) in patients with COPD and cardiac …
Effects of long-acting bronchodilators on cardiac autonomic control in COPD
S Elhage, L Laurent, K Diallo, M Bouhaddi… - … Medicine and Research, 2022 - Elsevier
… bronchodilators including long acting β2 agonists (LABAs) and muscarinic antagonists (LAMAs)
[2], [3], [4], [5]. This increased risk of cardiovascular events … this study used an inhaled …
[2], [3], [4], [5]. This increased risk of cardiovascular events … this study used an inhaled …
Adding a second bronchodilator in COPD: A meta-analysis on the risk of specific cardiovascular serious adverse events of tiotropium/olodaterol fixed-dose …
P Rogliani, BL Ritondo, B Zerillo… - … Pulmonary Disease, 2020 - Taylor & Francis
… adding a second long-acting bronchodilator in patients with … severe cardiovascular (CV) risk,
irrespective of prior CV disease … once daily via the Soft Mist Inhaler device Respimat®. The …
irrespective of prior CV disease … once daily via the Soft Mist Inhaler device Respimat®. The …